Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine.
Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
This prospective monocentric open label trial was realized in the Laboratory of Clinical
Functional Exploration of Movement at the University Hospital of Besancon. Cognitive
evaluations: 7 days before fampridine treatment initiation (Pre 1), on the day of fampridine
treatment initiation (Pre 2), 14 and 21 days after fampridine treatment initiation,
respectively Post 1 and Post 2. Gait evaluations were assessed at Pre 1, Pre 2 and Post 1.
Fampridine was prescribed according to guidelines issued by the French Health Products Safety
Agency at the dose of 10 mg twice daily. Fampridine is indicated for the improvement of
walking in MS patients with a walking disability (EDSS 4-6.5). A walking test is recommended
to evaluate improvement after 2 weeks of treatment. According to the practitioner evaluation
between Pre 2 and Post 1 (i.e. before and after fampridine treatment), patients were
classified into 2 groups: responders whose clinical status was improved and non-responders
whose clinical status was not improved.